Impact of maternal antibodies and microbiota development on the immunogenicity of oral rotavirus vaccine in African, Indian, and European infants by Parker, Edward PK et al.
ARTICLE
Impact of maternal antibodies and microbiota
development on the immunogenicity of oral
rotavirus vaccine in African, Indian, and
European infants
Edward P. K. Parker 1,11✉, Christina Bronowski 2,11, Kulandaipalayam Natarajan C. Sindhu 3,11, Sudhir Babji3,
Blossom Benny3, Noelia Carmona-Vicente2, Nedson Chasweka4, End Chinyama4, Nigel A. Cunliffe2,5,
Queen Dube4, Sidhartha Giri3, Nicholas C. Grassly 6, Annai Gunasekaran3, Deborah Howarth2,
Sushil Immanuel3, Khuzwayo C. Jere 2,4,7, Beate Kampmann 1, Jenna Lowe2, Jonathan Mandolo4,
Ira Praharaj3, Bakthavatsalam Sandya Rani3, Sophia Silas3, Vivek Kumar Srinivasan3, Mark Turner 8,
Srinivasan Venugopal3, Valsan Philip Verghese9, Alistair C. Darby2,12, Gagandeep Kang3,12 &
Miren Iturriza-Gómara 2,10,12✉
Identifying risk factors for impaired oral rotavirus vaccine (ORV) efficacy in low-income
countries may lead to improvements in vaccine design and delivery. In this prospective cohort
study, we measure maternal rotavirus antibodies, environmental enteric dysfunction (EED),
and bacterial gut microbiota development among infants receiving two doses of Rotarix in
India (n= 307), Malawi (n= 119), and the UK (n= 60), using standardised methods across
cohorts. We observe ORV shedding and seroconversion rates to be significantly lower in
Malawi and India than the UK. Maternal rotavirus-specific antibodies in serum and breastmilk
are negatively correlated with ORV response in India and Malawi, mediated partly by a
reduction in ORV shedding. In the UK, ORV shedding is not inhibited despite comparable
maternal antibody levels to the other cohorts. In both India and Malawi, increased microbiota
diversity is negatively correlated with ORV immunogenicity, suggesting that high early-life
microbial exposure may contribute to impaired vaccine efficacy.
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The roll-out of oral rotavirus vaccine (ORV) has nowreached over 100 countries. This initiative—in parallel withadvances in sanitation infrastructure and increased use of
oral rehydration therapy—has led to substantial declines in global
diarrhoeal mortality1. Whereas rotavirus was linked with over
500,000 infant deaths annually at the turn of the century2, this
number currently stands at approximately 130,0003. Yet the
potential impact of ORV is constrained by the impaired perfor-
mance of current vaccines in low- and middle-income countries
(LMICs). The 1-year protective efficacy of Rotarix against severe
rotavirus-associated gastroenteritis is >95% in Europe4 but may
fall below 50% in sub-Saharan Africa5. Moreover, while a variety
of interventions to boost ORV performance have been tested (e.g.
temporary withholding of breastfeeding), these have generally
proven either ineffective or of modest benefit6, highlighting the
need for new strategies informed by a deeper understanding of
the mechanisms underlying the vaccine efficacy gap.
A variety of risk factors have been linked with impaired oral
vaccine performance in LMICs7. Passively acquired maternal
antibodies appear to interfere with ORV immunogenicity8, as
documented for a variety of parenteral vaccines9. However, it
remains unclear whether rotavirus-specific antibody concentra-
tions and their inhibitory effect are higher in LMICs. Environ-
mental enteric dysfunction (EED)—a subclinical condition
associated with intestinal inflammation and increased perme-
ability—is common in LMICs and has been cited as a possible
cause of oral vaccine failure10. However, EED is generally mea-
sured using faecal or plasma markers as a proxy for mucosal
immune status, and studies of these markers at the time of oral
vaccine delivery have yielded mixed results11. The bacterial gut
microbiota shapes and is in turn shaped by the developing infant
immune system. Among infants in Ghana, Rotarix immuno-
genicity was positively correlated with the relative abundance of
Streptococcus bovis and negatively correlated with Bacteroidetes
abundance at the time of the first vaccine dose12. However, no
significant discrepancies in microbiota composition were appar-
ent when comparing Rotarix responders with non-responders in
India13. Consistent predictors of ORV failure within the bacterial
gut microbiota thus remain elusive.
Much of what we know about the mechanisms shaping oral
vaccine performance comes from single-population studies
focusing on individual risk factors. Here, we present a multicentre
cohort study exploring the effect of maternal antibodies, EED
markers, and bacterial gut microbiota development on Rotarix
response among infants in Malawi, India, and the UK.
Results
Study population. We enrolled pregnant women during the third
trimester in Vellore (India; n= 395), Blantyre (Malawi; n= 187),
and Liverpool (UK; n= 82). After delivery, infants received
routine vaccines including two doses of Rotarix according to the
national immunisation schedule (weeks of life 6 and 10 in India
and Malawi; weeks of life 8 and 12 in the UK). We measured
rotavirus-specific IgA (RV-IgA) in maternal blood, cord blood,
and breastmilk samples collected during or in the week after
delivery, and in infant blood samples collected pre- and post-
vaccination (4 weeks after dose 2). In Indian participants, all
serum samples were also assayed for rotavirus-specific IgG (RV-
IgG). Starting in the first week of life, six longitudinal stool
samples were collected from each infant and assayed for rotavirus
shedding, with samples collected 1 week after each ORV dose
providing an indicator of vaccine virus take. As a proxy for
bacterial microbiota development in the infant gut, we sequenced
the V3–V4 region of the 16S rRNA gene in stool samples col-
lected at 1 and 4 weeks of age, and before each ORV dose. EED
markers were measured in serum and/or stool samples collected
before each vaccine dose (Fig. 1A).
A total of 486 infants (307 in India, 119 in Malawi, and 60 UK),
born between December 2015 and April 2018, met the primary
endpoint for inclusion in the analysis (measurement of
seroconversion or dose 1 shedding). While the pre- and post-
parturition conditions of these disparate cohorts are innumerable,
several distinguishing features are highlighted in Table 1. Infants
in the UK were characterised by a higher birthweight and a
greater prevalence of formula feeding (though >75% were
partially or exclusively breastfed). Elective caesarean was an
exclusion criterion for the UK but was the mode of delivery for
70/307 (23%) infants in India. HIV exposure was common
among infants in Malawi (27/119 [23%]).
Other vaccines were administered according to the routine
schedule at each site, including OPV at 0, 6, and 10 weeks of age
in Malawi and India. In India, 98/307 (32%) infants were born
before April 2016—the date of the global switch from tOPV to
bOPV. Infants therefore received tOPV-only, bOPV-only, or
mixed schedules (Table 1). To explore the potential inhibitory
effect of OPV on ORV14, the 6 and 10 week doses of OPV were
replaced with inactivated poliovirus vaccine (IPV) in a sequen-
tially recruited cohort in India (100/307 [33%]). The comparison
of OPV and IPV arms is described elsewhere (Babji et al., in
preparation). Briefly, while shedding after the first dose of ORV
was less common in OPV than IPV recipients, cumulative
shedding after both doses was comparable in the two arms, as
were seroconversion rates and post-vaccination RV-IgA levels.
Given the lack of association between study arm and ORV
immunogenicity, we pooled the IPV and OPV arms in the present
study.
ORV shedding and immunogenicity. In the UK, we observed
near-ubiquitous shedding of the first dose of ORV, with 55/60
(92%) shedding 1 week after vaccination and 24/54 (44%) con-
tinuing to shed immediately prior to the second dose (4 weeks
after dose 1; Supplementary Fig. 1A). By contrast, dose 1 shed-
ding was detected in 82/305 (27%) infants in India and 56/101
(55%) in Malawi (Fig. 1B), and continued shedding prior to the
second dose was much rarer in these cohorts (Supplementary
Fig. 1A). Shedding following at least one dose was observed in 54/
56 (96%) infants in the UK, 151/304 (50%) in India, and 50/72
(69%) in Malawi (Fisher’s p values <0.005 for all between-country
comparisons after false discovery rate [FDR] adjustment; Fig. 1B).
We observed similar geographic discrepancies in ORV
immunogenicity. Baseline seropositivity was common in India
(99/305 [32%] compared to <5% in the UK and Malawi) due to
high rates of neonatal rotavirus infection (see below). Serocon-
version, defined as detection of RV-IgA at ≥20 IU/ml in
previously seronegative infants or a 4-fold increase in RV-IgA
concentration among infants who were seropositive at baseline,
was observed in 85/305 (28%) infants in India, 24/103 (23%)
infants in Malawi, and 27/51 (53%) infants in the UK (Fig. 1C).
Geometric mean concentrations (GMCs) of RV-IgA (IU/ml) after
vaccination were 20 (95% CI 16–25) in India, 9 (6–12) in Malawi,
and 27 (17–45) in the UK (Tukey’s post-hoc p values <0.005 for
comparisons between Malawi and other cohorts and 0.489 for
India vs UK). Among infants who seroconverted, post-
vaccination RV-IgA levels did not differ significantly among
cohorts (GMCs of 93 [73–118], 122 [80–187], and 105 [71–155]
in India, Malawi, and the UK, respectively; Tukey’s post-hoc p
values >0.05).
Neonatal rotavirus infection. A distinct feature among Indian
infants was the high rate of neonatal rotavirus infection, which we
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defined as the detection of wild-type rotavirus shedding in week
of life 1 (Fig. 1B) and/or baseline seropositivity (pre-vaccination
RV-IgA ≥20 IU/ml). This was observed in 166/304 (55%) infants
in India, whereas the corresponding rates were 10/90 (11%) in
Malawi and 2/54 (4%) in the UK. Neonatal infection in India was
more common among infants born in tertiary care facilities
(relative risk [RR] 1.98 [95% CI 1.72–2.19]; Supplementary
Table 1) and among infants delivered by caesarean section versus
vaginal delivery (RR 1.31 [1.05–1.53]). All neonatal rotavirus
infections were asymptomatic. We successfully characterised
infant week of life

























Fig. 1 Study design and oral rotavirus vaccine response. A Study design. The final study population comprised 307 infants in India, 119 in Malawi, and 60
in the UK. B, C Geographic differences in B rotavirus shedding and C ORV immunogenicity. Rotavirus shedding was detected via quantitative PCR using a
pan-rotavirus assay targeting the VP6 gene of group A rotaviruses (week of life 1) and an assay for vaccine virus shedding targeting the Rotarix NSP2 gene
(1 week after each dose). Seroconversion was defined as detection of RV-IgA at ≥20 IU/ml post-vaccination among infants who were seronegative at
baseline or a 4-fold increase in RV-IgA concentration among infants who were seropositive at baseline. Error bars represent Clopper–Pearson 95%
confidence intervals. Groups were compared by two-sided Fisher’s exact test with FDR correction (binary outcomes) or ANOVA with post-hoc Tukey tests
(continuous outcomes). The dotted lines at 20 IU/ml indicate the standard cut-off for RV-IgA seropositivity. Box plots display median (centre line), upper
and lower quartiles (box limits), the minimum value greater than or equal to the lower quartile− 1.5 × interquartile range (lower whisker), and the largest
value less than or equal to the upper quartile+ 1.5 × interquartile range (upper whisker). EED, environmental enteric dysfunction markers; IND, India; MLW,
Malawi; ns, not significant; ORV, oral rotavirus vaccine; RV, rotavirus; †, +2 weeks in UK due to later vaccination schedule; *p < 0.05; **p < 0.005;
***p < 0.0005.
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rotavirus genotype in 104 samples with detectable rotavirus
shedding at week of life 1, of which 103 were positive for the
strain G10P[11].
Consistent with the high prevalence of neonatal rotavirus
infection, we observed significantly higher pre-vaccination RV-
IgA concentrations in India compared with Malawi and the UK
(Fig. 1C). Neonatal infection was associated with a reduced
likelihood of dose 1 ORV shedding (RR 0.47 [0.30–0.71]). By
contrast, neonatal infection did not significantly influence the
likelihood of seroconversion (RR 1.25 [0.86–1.73]). Where ORV
shedding 1 week after either dose was observed among infants
with neonatal infection, this significantly boosted post-
vaccination RV-IgA concentrations, pointing to a cumulative
effect of neonatal infection and vaccination on overall immuno-
genicity (Supplementary Fig. 1B). Indeed, while the post-
vaccination GMCs of Indian infants lacking neonatal infection
were commensurate with those observed in Malawi (6 [5–8] vs 9
[6–12], respectively), the final antibody levels among Indian
infants with neonatal infection exceeded those observed in the
UK (55 [42–73] vs 27 [17–45], respectively).
Breastfeeding, growth, and sanitation. We examined several
baseline health and demographic variables for their potential
correlation with dose 1 ORV shedding (Supplementary Data 1),
seroconversion (Supplementary Data 2), and post-vaccination
RV-IgA (Supplementary Data 3). In India, seroconversion was
positively correlated with exclusive breastfeeding (RR 2.04
[1.07–3.68]) and was less common in infants who received tOPV-
containing than bOPV-only schedules (RRs of 0.56 [0.29–0.95]
for tOPV-only and 0.56 [0.29–0.95] for mixed tOPV/bOPV),
although the potential contribution of seasonal changes (e.g., in
enteropathogen exposure) to this trend cannot be discounted
given that OPV schedule was not randomly allocated. Similar
associations were apparent in India when considering post-
vaccination RV-IgA concentration as an endpoint (Supplemen-
tary Data 3). Moreover, RV-IgA levels were positively correlated
with height-for-age Z score at the time of the first ORV dose in
India (beta 1.32 [95% CI 1.07–1.63], where beta represents the
estimated ratio of GMCs per unit change in Z score), and was
higher among infants in India living in houses built from per-
manent versus temporary or mixed materials (beta 2.03
[1.26–3.26]) or with access to treated water (beta 1.66
[1.04–2.67])—both indicators of higher socioeconomic status.
Baseline health and demographic variables were not significantly
correlated with ORV response in Malawi or the UK, although
fewer covariates were measured in these cohorts (Supplementary
Data 1–3).
Maternal antibodies. Serum RV-IgA concentrations were sig-
nificantly higher among mothers in Malawi than in India or the
UK (Fig. 2A; GMCs of 134 [120–150], 340 [256–452], and 186
[123–281] in India, Malawi, and the UK, respectively). Interest-
ingly, maternal serum RV-IgA levels did not differ significantly
between India and the UK, while breastmilk RV-IgA concentra-
tions were significantly higher in Malawi and the UK than in
India (GMCs of 25 [22–29], 97 [84–112], and 100 [68–146] in
India, Malawi, and the UK, respectively). Reflecting the relative
deficit in breastmilk RV-IgA levels in India, maternal breastmilk/
serum RV-IgA ratios were significantly lower in this cohort than
both Malawi and the UK (Fig. 2B).
Our analysis of the association between maternal antibodies
and ORV outcome yielded several notable findings. First,
although maternal serum RV-IgA concentrations were not
significantly associated with seroconversion (RRs of 0.94
[0.78–1.12], 0.80 [0.61–1.01], and 0.91 [0.70–1.09] in India,
Malawi, and the UK, respectively; Supplementary Data 2), they
were negatively correlated with infant post-vaccination RV-IgA
levels in each cohort (Pearson coefficient [r] of −0.29, −0.13, and
−0.12 in Malawi, India, and the UK, respectively; Fig. 2C).
Although this correlation was not significant in the UK, we
observed no significant evidence of effect modification between
cohorts (p values of >0.05 for interaction terms between maternal
RV-IgA and country). Second, maternal serum RV-IgA levels
were negatively correlated with ORV shedding after dose 1 in
India (RR 0.75 [0.60–0.92]), particularly among infants with
neonatal infection (RR 0.50 [0.31–0.75]), and a similar trend was
evident in Malawi (RR 0.85 [0.67–1.00]; Supplementary Data 2).
By contrast, ORV shedding in the UK was ubiquitous despite the
fact that maternal antibody levels were equivalent to those in
India. Finally, we observed no significant difference in maternal
antibody levels according to rotavirus shedding in week of life 1
among Indian infants (Supplementary Table 1 and Fig. 2D),
suggesting that neonatal G10P[11] viruses may not be subject to
the same shedding inhibition observed for ORV. However,
among infants with neonatal infection (as defined above), we
observed a strong negative correlation between maternal RV-IgG
levels and infant RV-IgA at 6 weeks of age (r −0.42, p < 0.001;
Fig. 2C).
Disentangling the relative influence of breastmilk versus
transplacental antibodies is challenging given the correlation
between the two (r of 0.29, 0.39, and 0.29 in India, Malawi, and
the UK, respectively; Fig. 2D). As observed for maternal serum
RV-IgA, breastmilk RV-IgA was not significantly correlated with
seroconversion in any cohort (Supplementary Data 3), but was
negatively correlated with infant post-vaccination RV-IgA levels
in India and Malawi (r of −0.14 and −0.26, respectively; Fig. 2C).
Breastmilk RV-IgA was negatively correlated with ORV shedding
after dose 1 in India (RR 0.83 [0.69–0.98]; Supplementary Data 2)
but not in Malawi (RR 0.91 [0.58–1.23]).
Table 1 Baseline characteristics of study cohorts.
India Malawi UK
N 307 119 60
Month of birth
First 12/2015 11/2016 09/2016
Last 11/2016 04/2018 03/2018
Caesarean delivery 70 (22.8) 0 (0.0) 1 (1.7)a
Birthweight (kg) 2.96 (0.42) 3.02 (0.42) 3.68 (0.48)
Female 152 (49.5) 60 (50.4) 24 (40.0)
Polio vaccine schedule
tOPV 57 (18.6) — —
Mixed tOPV/
bOPV
56 (18.2) — —
bOPV 94 (30.6) 119 (100.0) —
IPV 100 (32.6) — 60 (100.0)
Breastfeedingb
Exclusive 265 (86.3) 108 (90.7) 26 (43.3)
Partial 32 (10.4) 11 (9.2) 20 (33.3)
None 10 (3.3) 0 (0.0) 14 (23.3)
Exposed to
antibioticsc
84 (27.4) 33 (27.7) 6 (10.0)
HIV status
Exposed 0 (0.0) 27 (22.7) —
Unexposed 299 (97.4) 88 (73.9) —
Unknown 8 (2.6) 4 (3.4) 60 (100.0)
Data are n (%) or mean (s. d.).
aElective caesarean was an exclusion criterion for this cohort (with 1 delivery by emergency
caesarean).
bData from birth to week of life 11 in Malawi and India, and birth to week of life 13 in the UK.
cData from birth to week of life 14 in Malawi and India, and birth to week of life 13 in the UK.
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Inflammatory biomarkers. We observed strong geographic dis-
crepancies in EED markers. Whereas α1-antitrypsin (α1AT; a
marker of protein-losing enteropathy) was highest in Malawi and
lowest in the UK, both myeloperoxidase (MPO; a marker of
neutrophil activity) and α1 acid glycoprotein (a marker of sys-
temic inflammation) were highest in Indian infants (Supple-
mentary Fig. 2A). Despite their marked variation within and
between cohorts, none of the biomarkers were significantly
associated with seroconversion, dose 1 ORV shedding, or post-
vaccination RV-IgA (Supplementary Fig. 2B and Supplementary
Data 1–3).
Geographic differences in microbiota development. We
sequenced 2137 separate faecal samples from the study popula-
tion, of which 2086 yielded high-quality microbiota profiles
(≥25,000 sequences after quality filtering; 143,123 ± 136,113
[mean ± s.d.] sequences per sample). Microbiota profiles were
consistent across sequencing runs and facilities (explored by
independently re-sequencing 10% of samples; Supplementary
Fig. 3). Infant samples contained 461 genera, of which a small
number were dominant (Supplementary Fig. 4). The trajectory of
microbiota development was highly distinct to each cohort, with
significant deviations apparent as early as the first week of life.
Microbiota diversity was significantly higher in Malawi than both
other cohorts (Fig. 3A), although this discrepancy receded with
increasing age. Inter-individual differences accounted for 58% of
variation in microbiota composition based on permutational
multivariate analysis (PERMANOVA; p= 0.001, 999 permuta-
tions), while country accounted for 6–9% of variation depending
on age (Fig. 3B). Based on longitudinal mixed-effects models, 12
genera (including Prevotella, Sutterella, Corynebacterium, and
Acinetobacter) were enriched across infancy in Malawi compared
with both India and the UK (Supplementary Fig. 5). On the other
hand, Bifidobacterium, Enterococcus, Staphylococcus, and Strep-
tococcus were enriched in Indian infants compared with both
other cohorts, while Bacteroides, Citrobacter, Enterobacter, Hae-
mophilus, and Klebsiella were enriched in the UK (Fig. 3B and
Supplementary Fig. 5). Numerous other discriminant taxa were
identified during cross-sectional analyses of genus prevalence and
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N, maternal serum RV-IgA 166 305 103 45 166 138
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Fig. 2 Association between maternal antibodies and oral rotavirus vaccine response. A Geographic differences in maternal antibody concentrations.
Groups were compared by ANOVA with post-hoc Tukey tests. The dotted lines at 20 IU/ml indicate the standard cut-off for RV-IgA seropositivity.
B Geographic differences in maternal breastmilk/serum RV-IgA ratios. Groups were compared by Dunn’s test. Ratios were calculated using log-
transformed antibody concentrations. See Fig. 1 legend for box plot parameters. C Association between maternal antibodies and infant RV-IgA formation.
Log-transformed concentrations were compared using Pearson’s correlation coefficient (r) with two-sided hypothesis testing. Infant samples for RV-IgA
measurement were collected at the time of dose 1 (week of life 6 in India/Malawi; week of life 8 in the UK) and 4 weeks after dose 2 (week of life 14 in
India/Malawi; week of life 16 in the UK). D Correlation between rotavirus-specific antibody concentrations and rotavirus shedding in Indian infants with
complete data (n= 298). For shedding variables, 1/Ct was used such that higher values correspond to higher rotavirus quantities. Shedding after week of
life 1 was determined based on the group A rotavirus VP6 gene assay (Ct range 23.5–35.0) while shedding after dose 1 was based on the Rotarix-specific
NSP2 gene assay (Ct range 20.7–40.0). Variables were compared using Spearman’s rank correlation coefficient (rho) with two-sided hypothesis testing.
neo+, infected with rotavirus neonatally (defined by detection of rotavirus shedding in week of life 1 or baseline seropositivity); neo−, uninfected with
rotavirus neonatally; ns, not significant; ORV, oral rotavirus vaccine; RV, rotavirus; *p < 0.05; **p < 0.005; ***p < 0.0005.
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and Supplementary Data 4). Moreover, using the machine-
learning method Random Forests, samples could be accurately
distinguished by country at all timepoints based on genus relative
abundances (median cross-validation accuracies of 80–90% for
infant samples; baseline accuracy 50%; Fig. 3D, E).
To explore cofactors associated with the developing microbiota
in each cohort, we performed an exploratory analysis of alpha and
beta diversity among samples collected at the time of the first
ORV dose (Supplementary Fig. 6A). Based on PERMANOVA of
genus-level unweighted Bray–Curtis distances, microbiota com-
position in India was significantly correlated with α1AT (R2
3.6%), breastfeeding status (R2 2.0%), age at vaccine delivery (R2
1.3%), and delivery mode (R2 1.1%), though only breastfeeding
status was significantly correlated with microbiota diversity
(mean [s.d., n] Shannon index of 1.2 [0.4, 248] in exclusively
breastfed infants vs 1.5 [0.4, 41] in infants with partial or no
breastfeeding; FDR p < 0.001). Neonatal rotavirus infection was
not significantly correlated with microbiota composition or
diversity (Supplementary Fig. 6B). In Malawi, microbiota
composition was associated with maternal RV-IgA level (R2
4.8%), α1AT (R2 4.5%), HIV exposure (R2 4.5%), and maternal
age (R2 4.1%). α1AT and maternal RV-IgA were positively
correlated with microbiota diversity. No covariates were sig-
nificantly associated with alpha or beta diversity in the UK after
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Fig. 3 Geographic differences in microbiota development. A Longitudinal analysis of alpha diversity. Shannon index was calculated at genus level. Cross-
sectional comparisons were performed using ANOVA with post-hoc Tukey tests. Longitudinal comparisons were performed using mixed-effects
regressions with week of life as a covariate and study ID as a random effect. Pairwise longitudinal comparisons between countries were FDR corrected. See
Fig. 1 legend for box plot parameters. B Proportion of variation in microbiota composition associated with country. R2 and statistical significance were
determined by PERMANOVA using genus-level unweighted Bray–Curtis distances. C Longitudinal plot of mean genus abundances. Genera are displayed if
they were present with a mean relative abundance of ≥5% in at least one country at one or more timepoints. D Cross-validation accuracy of Random
Forests for prediction of country. Genus relative abundances served as input for each model. Median out-of-bag accuracy (proportion correctly assigned)
and interquartile range across 20 iterations of 5-fold cross-validation are displayed. A random subset of 50 samples per country was used for each
iteration. E The 10 most important genera selected by Random Forests for discriminating infants by country at the time of the first dose of ORV. Mean
cross-validation importance scores based on Gini index are depicted alongside the prevalence and mean abundance of the corresponding genera in each
country. C, country; CV, cross-validation; IND, India; MLW, Malawi; ns, not significant; †, +2 weeks in UK due to later vaccination schedule; *p < 0.05;
**p= 0.001; ***p < 0.0005.
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Microbiota composition versus ORV response. In both India
and Malawi, microbiota diversity was negatively correlated with
ORV seroconversion (Fig. 4A) and post-vaccination RV-IgA
concentration (Supplementary Fig. 7A). In India, the dis-
crepancies by seroconversion status were apparent in longitudinal
models as well as cross-sectional comparisons at weeks of life 4
and 6. Interestingly, stratified analyses in India revealed the dis-
crepancies to be specific to infants with no neonatal rotavirus
infection (Fig. 4A and Supplementary Fig. 7A). These associations
were robust in sensitivity analyses restricted to exclusively
breastfed infants or those born by vaginal delivery (p values of
0.008 and 0.004 for respective longitudinal models of microbiota
diversity; Supplementary Fig. 8). Similar discrepancies in micro-
biota diversity were evident in Malawian infants, albeit specifi-
cally at the time of the first dose of ORV. By contrast, microbiota
diversity was not strongly associated with ORV seroconversion or
post-vaccination RV-IgA concentration in the UK, and was not
significantly associated with ORV shedding after dose 1 in any
cohort (Supplementary Fig. 9A).
These results are corroborated by cross-sectional analyses of
beta diversity. Based on PERMANOVA of unweighted
Bray–Curtis distances, microbiota composition was significantly
but modestly (R2 < 4%) correlated with seroconversion (Fig. 4B)
and post-vaccination RV-IgA (Supplementary Fig. 7B) in
Malawian infants as well as Indian infants without neonatal
rotavirus infection. However, we did not observe clear differences
in taxonomic composition according to ORV response. Cross-
sectional Random Forests models based on genus or ribosomal
sequence variant (RSV) abundances failed to accurately predict
seroconversion (Fig. 4C), post-vaccination RV-IgA (Supplemen-
tary Fig. 7C), or ORV shedding after dose 1 (Supplementary
Fig. 9C). After FDR correction, we did not observe significant
differences in the prevalence (based on Fisher’s exact test) or
abundance (based on Aldex2) of individual genera or RSVs
according to ORV outcome. Likewise, longitudinal models of
common genera (present in ≥20% of samples) revealed numerous
age-associated changes in abundance, but very few taxa with
differential abundance according to ORV outcome (Supplemen-
tary Table 2). Overall, while microbiota diversity appears to be
significantly higher among infants in India and Malawi who fail
to respond to ORV, we did not observe consistent discrepancies
in specific bacterial taxa according to vaccine outcome.
Multivariate analysis. To delineate the contribution of different
risk factors in shaping ORV response, we used the machine-
learning algorithm Random Forests to predict ORV outcome
based on a combination of: (i) demographic and baseline health
variables (n= 18; see Supplementary Data 2 for complete list); (ii)
exposure/antibody data (n= 12), including EED markers and
maternal antibody concentrations; and (iii) genus relative abun-
dances at the time of the first ORV dose (week of life 6; n= 55).
These analyses focused on Indian infants given the larger size of
this cohort (n= 249 with complete data). Moreover, we included
analyses stratified by neonatal rotavirus infection status given its
modifying effect on the associations reported above. Models
exhibited poor accuracy for the prediction of seroconversion and
ORV shedding after dose 1 (Fig. 5A). Post-vaccination RV-IgA
concentration was predicted with modest accuracy (R2 of 37.2%;
interquartile range [IQR] 31.4–42.5%)—an effect driven primarily
by neonatal rotavirus infection (Fig. 5B). Prediction of post-
vaccination RV-IgA was markedly reduced in the stratified ana-
lyses (R2 of 16.1% [9.6–22.1%] and 3.7% [0.3–5.1%] in infants
with and without neonatal infection, respectively). Maternal RV-
IgG was the most important predictor of post-vaccination RV-
IgA among infants with neonatal infection, whereas multiple
maternal antibody and microbiota variables were among the top-
ranking features for infants without neonatal infection (Fig. 5B).
We complemented the machine-learning models with multi-
variate regressions. Covariates with a p value of <0.05 in
univariate analyses were selected for inclusion in these models.
Consistent with the Random Forests outputs, few significant
predictors were identified for multivariate models of seroconver-
sion among Indian infants (Supplementary Data 2). ORV
shedding after dose 1 in this cohort was negatively correlated
with neonatal rotavirus infection (RR 0.51 [0.30–0.80]) and
maternal RV-IgA (RR 0.68 [0.53–0.85]), and was higher in the
sequentially recruited cohort of IPV recipients (RR 2.18
[1.41–3.08]; see Supplementary Data 1 for full results). Neonatal
rotavirus infection was the most important predictor of post-
vaccination RV-IgA in Indian infants, while breastfeeding
practice, linear growth, maternal RV-IgG, and polio vaccine
schedule were also significant predictors for this outcome (Table 2;
see Supplementary Data 3 for full univariate and multivariate
results). Associations varied according to neonatal rotavirus
infection status—whereas maternal RV-IgG concentration and
breastfeeding status were the strongest predictor of post-
vaccination RV-IgA among infants with neonatal rotavirus
infection, significant predictors of RV-IgA in those lacking
neonatal infection included microbiota diversity, house type, and
access to treated water. Overall, the multivariate regressions
offered a predictive accuracy commensurate with or exceeding
that of Random Forests (R2 of 43% in the complete cohort and
11–19% in the stratified analyses for RV-IgA regressions;
Table 2).
Discussion
ORV is unique among oral vaccines in being routinely adminis-
tered in both high-income countries and LMICs. As such, the
vaccine provides a valuable tool for probing the divergent tra-
jectories of the developing immune system in different settings.
Here, we report on the extent to which several key determinants
of infant immune development differ among three disparate
populations, and the degree to which these factors shape ORV
response.
As expected, Rotarix response was significantly impaired among
infants in Malawi and India. While the later vaccination schedule in
the UK (8/12 weeks vs 6/10 weeks) may contribute to these dif-
ferences by providing more time for passively acquired maternal
antibodies to wane, overall shedding rates after both doses in
Malawi and India still fell short of the near-ubiquitous dose
1 shedding observed in the UK, highlighting the barriers to ORV
that emerge within the first weeks of life in LMICs. Seroconversion
rates in India and Malawi were broadly consistent with those pre-
viously reported in LMICs15,16, but lower than expected in the
UK17. These findings highlight the suboptimal nature of serum RV-
IgA as a correlate of protection. While higher RV-IgA concentra-
tions correlate with a lower risk of subsequent rotavirus infection,
these associations often fail to hold when considering protection
against rotavirus-associated gastroenteritis18. Although ORV shed-
ding has not been validated as a correlate of protection, our study
highlights the potential value of this outcome in capturing divergent
ORV responses within and between populations. We advocate the
further use of vaccine virus shedding in the week after adminis-
tration (at multiple timepoints where possible) as an adjunctive
measure of ORV response in future trials. Faecal RV-IgA has also
been shown to correlate with protection against rotavirus illness and
merits further consideration in infant vaccine trials19.
For a risk factor to account for broad geographic trends in
ORV efficacy, it is reasonable to expect it to be more common or
observed at higher levels in LMICs than high-income countries.
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N seroconversion+ 79 76 79 79 18 15 12 9 27 26 25 25 47 46 46 49 32 30 33 30
N seroconversion 208 209 208 202 55 56 54 44 23 24 23 24 108 110 108 111 99 98 99 90
N per RF iteration 100 100 100 100 36 30 24 46 48 46 48 96 92 92 98 64 60 66 60
N genera included 49 61 62 72 150 154 123 127 45 71 75 83 55 60 65 70 54 57 65 77
N discriminant genera 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
N RSVs included 160 182 189 223 601 692 505 445 184 223 237 261 161 193 189 217 194 200 235 262
N discriminant RSVs 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
N seroconversion+ 79 76 79 79 18 15 12 9 27 26 25 25 47 46 46 49 32 30 33 30
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Fig. 4 Association between microbiota development and oral rotavirus vaccine seroconversion. A Longitudinal analysis of alpha diversity. Shannon index
was calculated at genus level. Cross-sectional comparisons were performed using logistic regression. Longitudinal comparisons were performed using mixed-
effects models including week of life as a covariate and study ID as a random effect. See Fig. 1 legend for box plot parameters. B Proportion of variation in
microbiota composition associated with seroconversion. R2 and statistical significance were determined by PERMANOVA using genus-level unweighted
Bray–Curtis distances. C Cross-validation accuracy of Random Forests for prediction of seroconversion. Models were fitted at genus and RSV level. Median out-
of-bag accuracy (proportion correctly assigned) and interquartile range across 20 iterations of 5-fold cross-validation are displayed. Each iteration included an
equal number of responders and non-responders (50 per group where possible, or else the number in the minority group if this was <50). For each cross-
sectional comparison, taxa were classified as discriminant if they had an FDR-adjusted p value of <0.05 based on either two-sided Fisher’s exact test
(differences in prevalence) or Aldex2 with two-sided Wilcoxon rank-sum test (differences in abundance). CV, cross-validation; IND, India; MLW, Malawi; neo+,
infected with rotavirus neonatally (defined by detection of rotavirus shedding in week of life 1 or baseline seropositivity); neo−, uninfected with rotavirus
neonatally; nf, not fitted as <10 responders; ns, not significant; RF, Random Forests; RSV, ribosomal sequence variant; *p < 0.05; **p < 0.005; ***p < 0.0005.
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This was not the case for several of the factors examined in this
study. Maternal serum RV-IgA levels were comparable in the UK
and India (although significantly higher in Malawi), while
breastmilk RV-IgA levels were higher in the UK than in India.
These results are somewhat surprising given that recent rotavirus
exposure and consequent boosting of antibody levels might be
expected to occur more frequently among mothers in LMICs with
a high rotavirus disease burden. In previous studies, RV-IgA
concentrations were significantly higher in India than the USA,
with intermediate levels in South Africa20,21. Our findings caution
against the broader extrapolation of these trends. The high
maternal RV-IgA levels in the UK may reflect the immunogenic
nature of early rotavirus exposures and the subsequent boosting
of antibodies by mild or asymptomatic re-infection22. Nutritional
stress has also been linked with lower secretory IgA levels in
breastmilk23,24. Consistent with this, we observed maternal
breastmilk/serum RV-IgA ratios to be lowest in India and highest
in the UK, with intermediate levels in Malawi.
Although maternal antibody concentrations did not follow a
clear geographic gradient, our findings confirm the potential
inhibitory effect of these antibodies on ORV among infants in
LMICs. Whereas previous studies of this phenomenon have
typically focused on immunogenicity endpoints8,25, we observed a
link with both shedding and immunogenicity, suggesting that the
effect of maternal antibodies may be mediated in part through a
reduction in ORV shedding. This could potentially involve the
transudation of transplacental RV-IgG across the mucosal
epithelium or the direct neutralisation of vaccine viruses by RV-
IgA in breastmilk. Our findings are also consistent with the
inhibition of downstream antigen processing by transplacental
antibodies, as evidenced by the strong inverse correlation between
maternal RV-IgG and infant RV-IgA formation pre-vaccination
in Indian infants with neonatal rotavirus infection. Overall, one
could reasonably envision a combination of upstream inhibition
of ORV shedding (via RV-IgA or transudated RV-IgG) and
downstream inhibition of antigen processing (via circulating RV-
IgG) that synergistically inhibit ORV outcome. However, these
mechanisms alone are clearly insufficient to prevent a robust
ORV response given that the vaccine was ubiquitously shed and
was most immunogenic in the UK, where maternal antibody
levels were high and >75% of infants were breastfed. Moreover,
exclusive breastfeeding was positively correlated with post-
vaccination RV-IgA in Indian infants, suggesting that any inhi-
bitory effect of RV-IgA in milk are offset by the potential benefits
of breastfeeding for ORV, such as the buffering of gastric acid.
We considered several markers as a proxy for EED. Although
α1AT concentrations were significantly lower in the UK than
both other cohorts, MPO levels were similar in the UK and
Malawi, calling into question the extent to which this marker
accurately captures the onset of EED. We did not observe a sig-
nificant relationship between any of the measured EED markers
and ORV outcome, in keeping with the growing literature in this
field11,26. Together, these findings imply either that EED is not a










N per RF iteration 100 76 52
N responders 64 95 26
N non-responders 185 38 90
249 133 116
IND, N with complete data: 249
Fig. 5 Integrated analysis for prediction of oral rotavirus vaccine response in indian infants. A Cross-validation accuracy of Random Forests models for
prediction of ORV response based on demographic variables, exposure/antibody variables, and genus relative abundances at the time of dose 1 (week of
life 6). Infants with complete data were included. Median out-of-bag accuracy and interquartile range across 20 iterations of 5-fold cross-validation are
displayed. For binary outcomes (seroconversion and shedding), each iteration included an equal number of responders and non-responders (50 per group
where possible, or else the number in the minority group if this was <50). Out-of-bag accuracy reflects the proportion of infants correctly assigned (binary
outcomes) or R2 for predicted vs observed outcome (RV-IgA). B The top 10 variables selected by Random Forests for prediction of post-vaccination RV-
IgA concentration based on mean cross-validation importance score. CV, cross-validation; HAZ, height-for-age Z score; IND, India; IPV, inactivated
poliovirus vaccine; neo+, infected with rotavirus neonatally (defined by detection of rotavirus shedding in week of life 1 or baseline seropositivity); neo−,
uninfected with rotavirus neonatally; MPO, myeloperoxidase; MSE, mean squared error; OPV, oral poliovirus vaccine; ORV, oral rotavirus vaccine; RF,
Random Forests; RV, rotavirus.
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not accurately captured by the current suite of faecal and systemic
markers. However, we observed a negative correlation between
post-vaccination RV-IgA and height-for-age Z score in Indian
infants, corroborating recent data from Zimbabwe linking growth
deficits with impaired ORV response14.
A key finding of translational relevance is the highly immu-
nogenic nature of neonatal rotavirus infection in India. Neonatal
infection was detected in almost half of the infants in this cohort,
and these infants exhibited significantly higher final RV-IgA
concentrations than uninfected infants. Machine-learning models
corroborated this by selecting neonatal rotavirus infection status
as the most important determinant of final RV-IgA concentration
out of 85 input variables. Neonatal infection with the G10P[11]
strain was not sensitive to the inhibitory effect of maternal
antibody levels (a trait also reported for the G3P[6] oral human
neonatal rotavirus vaccine candidate RV3-BB27), potentially
reflecting serotype-specific adaptation to the newborn gut28
alongside reduced exposure to RV-IgA and other antiviral com-
pounds if infection occurs prior to breastfeeding. Trials exploring
the shedding and immunogenicity of Rotarix (a G1P[8] strain)
when administered neonatally would help distinguish these pos-
sibilities. In Indonesia, RV3-BB efficacy against severe rotavirus
gastroenteritis was 75% when administered according to a neo-
natal schedule (weeks 1, 8, and 14) and 51% when administered
on a later schedule (weeks 8, 14, and 18), highlighting the efficacy
of schedules that include ORV at birth29.
We observed marked geographic discrepancies in composition
of the bacterial microbiota. Microbiota diversity was significantly
higher among Malawian infants, while Indian infants were dis-
tinguishable by their high Bifidobacterium abundance. The latter
is interesting given that Bifidobacterium has previously been
suggested to enhance immunological memory responses to a
range of vaccine targets30, but was least abundant among infants
in the UK that were most responsive to ORV. Similarly, we failed
to recapitulate other associations that have been documented
between bacterial microbiota composition and ORV outcome,
such as the higher abundance of Bacteroidetes among non-
responders in Ghana12. Although we did not record any clear
discrepancies in taxon abundances according to ORV response,
we observed a significant negative correlation between microbiota
diversity and vaccine immunogenicity among Indian and Mala-
wian infants. In India, the correlation was strongest in infants
lacking neonatal rotavirus infection, and was robust in sensitivity
analyses restricted to exclusively breastfed or vaginally delivered
infants. Given that infant microbiota diversity was comparable in
India and the UK, this factor alone is clearly insufficient to
account for broad geographic trends in ORV response. However,
the observation of a consistent microbiota signature of impaired
vaccine response across multiple LMICs is noteworthy. It is
plausible that early-life exposure to greater microbial diversity
(including members of the virome and eukaryome not measured
here) may foster a state of hyporesponsiveness at the mucosal
epithelium that impairs oral vaccine outcome in LMICs. Impaired
vaccine response could thus be viewed as a counterpart to
hyperresponsive immune states associated with low early-life
microbiota diversity, such as atopic disease31. Our findings in
Indian infants also support the notion that the neonatal period
represents a key window of microbiome development32. Indeed,
associations between microbiota diversity and ORV response in
this cohort were apparent from the first week of life onwards.
While a growing body of literature has emphasised the impor-
tance of microbiota composition in relation to health outcomes
such as malnutrition among children in LMICs33,34, studies
focusing on the first days and weeks of life are presently lacking,
and represent a crucial avenue of future research.
Table 2 Multivariate regression for post-vaccination rotavirus-specific IgA concentration in Indian infants.
variable univariate multivariate
beta (95% CI) p beta (95% CI) p
IND n= 286; adjusted R2: 43.4%
Delivery mode (caesarean vs vaginal) 2.04 (1.19–3.49) 0.010 1.45 (0.93–2.28) 0.102
Delivery place (tertiary vs non-tertiary) 2.69 (1.72–4.22) <0.001 1.08 (0.72–1.64) 0.701
Breastfeeding practice (exclusive vs non-exclusive) 2.29 (1.18–4.45) 0.015 1.89 (1.11–3.22) 0.019
Height-for-age Z score (week of life 6) 1.32 (1.07–1.63) 0.008 1.31 (1.10–1.55) 0.002
Exposed to rotavirus pre-vaccination 9.34 (6.37–13.71) <0.001 8.48 (5.67–12.67) <0.001
Polio vaccine schedule: bOPV only ref — ref —
bOPV/tOPV mixed 0.54 (0.28–1.05) 0.070 0.48 (0.28–0.85) 0.011
tOPV only 0.49 (0.25–0.96) 0.038 0.43 (0.25–0.75) 0.003
IPV 0.55 (0.31–0.97) 0.041 0.77 (0.49–1.22) 0.265
House made of permanent materials (yes vs no) 2.03 (1.26–3.26) 0.004 1.28 (0.86–1.91) 0.228
Access to treated water (yes vs no) 1.66 (1.04–2.67) 0.035 1.35 (0.93–1.96) 0.120
Maternal RV-IgG (IU/ml), log-transformed 0.59 (0.47–0.73) <0.001 0.59 (0.49–0.71) <0.001
IND neo+ n= 166; adjusted R2: 19.4%
Breastfeeding practice (exclusive vs non-exclusive) 4.08 (1.81–9.18) 0.001 3.45 (1.62–7.33) 0.001
Height-for-age Z score (week of life 6) 1.39 (1.08–1.79) 0.012 1.25 (0.99–1.58) 0.061
Maternal RV-IgG (IU/ml), log-transformed 0.50 (0.38–0.65) <0.001 0.54 (0.41–0.70) <0.001
IND neo– n= 124; adjusted R2: 10.8%
Delivery mode (caesarean vs vaginal) 2.58 (1.31–5.06) 0.006 1.74 (0.81–3.73) 0.153
Delivery place (tertiary vs non-tertiary) 1.93 (1.04–3.58) 0.036 1.17 (0.60–2.28) 0.637
House made of permanent materials (yes vs no) 1.84 (1.11–3.07) 0.019 1.72 (1.02–2.92) 0.043
Access to treated water (yes vs no) 2.04 (1.22–3.42) 0.007 1.82 (1.08–3.08) 0.026
Shannon (week of life 6) 0.52 (0.28–0.99) 0.047 0.48 (0.26–0.90) 0.021
Log-transformed RV-IgA concentration measured 4 weeks after dose 2 (week of life 14) served as the dependent variable. Variables with a p value of <0.05 during univariate analyses are shown here.
Full univariate regression results are provided in Supplementary Data 3. Infants with complete data for all selected covariates were included in multivariate models. Equivalent results for dose 1 ORV
shedding and seroconversion are provided in Supplementary Data 1 and 2, respectively.
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Despite the multiple demographic, immunological, and
microbiota variables considered, our overall ability to account for
discrepancies in ORV response within and between cohorts was
limited. Alternative risk factors for impaired ORV outcome must
therefore be considered. In particular, we would advocate further
efforts to profile early-life host–microbe interactions in LMICs,
including high-throughput measurements of breastmilk (e.g.
metabolome, microbiome, and antibody functionality) and faecal
samples (e.g. virome and metabolome). This will help to deter-
mine the extent to which metabolic and microbial exposures
combine to inhibit ORV response over the early weeks of life. The
epigenome merits further consideration given that BCG-induced
epigenetic remodelling of monocytes has been linked with pro-
tection against heterologous viruses35. It is also possible that we
considered the correct mechanisms but failed to capture them
with sufficient granularity using the methods and samples avail-
able. Alternative EED markers may be required to accurately
characterise the onset of this condition in early life. Moreover,
given the potential for overall microbial load to vary substantially
from infant to infant, absolute as opposed to relative quantitation
of microbial abundances may be necessary to capture the inter-
play between the developing bacterial microbiota and ORV
outcome36.
Our study has several limitations. First, as noted above, RV-
IgA is a suboptimal correlate of protection. We compensated for
this by considering multiple endpoints, including seroconversion
and post-vaccination shedding, though longer-term follow-up for
rotavirus-associated gastroenteritis was beyond the scope of the
study. Second, challenges in sample recruitment in Malawi meant
that the final study population (n= 119) fell short of the target
sample size (n= 150). This was exacerbated by incomplete
sample availability for recruited infants, such that several com-
parisons in this cohort may have been underpowered. Relatedly,
comparisons of post-vaccination RV-IgA across cohorts may
have been underpowered given the lower-than-expected ser-
oconversion rates in the UK. Finally, whilst the potential con-
tribution of batch effects to the observed differences between
populations cannot be completely ruled out, we went to con-
siderable lengths to ensure reproducibility and comparability
across sites, using the same reagent lots and standards. In the case
of microbiota composition, we independently re-sequenced 10%
of samples at a separate facility and recapitulated the original
microbiota composition with high accuracy.
Notwithstanding these caveats, this study advances our
understanding of the potential mechanisms influencing ORV
response in several ways. By considering how several risk factors
of ORV failure differ within and between populations, we have
been able to place these mechanisms within a broader global
context. Our study confirms the inhibitory effect of maternal
antibodies on ORV immunogenicity in LMICs, and suggests this
may be mediated partly by a reduction in ORV shedding. We
observed that asymptomatic neonatal rotavirus infection was
strongly associated with RV-IgA formation, providing further
support for the potential of neonatal vaccination as a pragmatic
approach to achieve greater rotavirus vaccine impact. Finally,
while specific bacterial taxa do not appear to drive within-
population differences in ORV response, high microbiota diver-
sity in early life may contribute to the impaired efficacy of this
vaccine in LMICs.
Methods
Study design. Pregnant women were enrolled during the third trimester at three
study sites: Blantyre (Malawi), Vellore (India), and Liverpool (UK). Women were
included if they provided informed written consent to participate in the study and
were willing to stay in the study area for 4 months following delivery. Exclusion
criteria included: congenital immune deficiency; chronic renal or liver failure; other
chronic illnesses which may affect immune function; non-singleton pregnancy; low
birthweight or pre-term birth (<34 weeks gestation); congenital anomalies and
other neonatal complications requiring prolonged hospitalisation; and delivery by
elective caesarean (UK only). Mothers provided a venous blood sample as well as a
cord blood sample during birth and a stool sample during the week after delivery.
Infants provided two blood samples (weeks of life 6 and 14 in India and Malawi;
weeks of life 8 and 16 in the UK) and six stool samples over the course of the study
(Fig. 1A), including samples at the time of each ORV dose (weeks of life 6 and 10 in
Malawi and India; weeks of life 8 and 12 in the UK). For post-vaccination rotavirus
shedding assays (weeks of life 7 and 11 in Malawi and India; weeks of life 9 and 13
in the UK), stool samples provided within ±1 days of the target were considered
eligible for inclusion. For all other timepoints, serum and stool samples provided
within ±3 days were considered eligible. Overall, we enrolled 664 mother–infant
dyads (395 in India, 187 in Malawi, and 82 in the UK). The primary endpoint
(measurement of seroconversion or dose 1 shedding) was reached by 484 dyads
(307 in India, 119 in Malawi, and 60 in the UK). The study was approved by the
Institutional Review Board at the Christian Medical College (CMC) in Vellore, the
College of Medicine Research and Ethics Committee in Blantyre, and the North
West—Liverpool East Research Ethics Committee in Liverpool. The trial is regis-
tered with the Clinical Trials Registry of India (CTRI/2015/11/006354) and the
study protocol has previously been published37.
Sample processing and storage. Whole blood was collected in anti-coagulation
EDTA-tubes (BD) and stored at 4 °C for up to 12 h until collection by laboratory
staff. Fractions were separated by centrifugation at 1500–2000 × g in a benchtop
centrifuge (Eppendorf). A disposable plastic transfer pipette was used to aspirate
the plasma down to ~1 mm from the red blood cells. The plasma was aliquoted into
two screw cap cryo-tubes (Starlab). The buffy coat and red blood cells were sub-
sequently collected into separate cryovials and all samples were stored at −70 °C.
Stool and breastmilk samples were collected in sterile sample pots by
participants and were shipped to the respective laboratory by courier within 24 h in
the UK and within 4 h in India and Malawi (to account for ambient temperatures).
Samples were kept at 4 °C for a maximum of 8 h until processing. Breastmilk
samples were stored in 2 ml aliquots in SuperLock tubes (Starlab) at −70 °C for
maternal RV-IgA analysis. Two 10% stool suspensions were prepared in sterile
phosphate-buffered saline (PBS) for assessing rotavirus shedding. Further aliquots
of neat stool were stored in 2 ml SuperLock tubes (Starlab) at −70 °C for
microbiota analysis and inflammatory biomarker measurement. Stool samples were
stored at −70 °C for a maximum of 2 weeks prior to DNA extraction for
microbiota analysis.
Rotavirus-specific antibodies. RV-IgA and RV-IgG laboratory assays were con-
ducted at CMC, Vellore, for samples from all three study sites using a custom
antibody-sandwich ELISA38. However, a technical issue with the assay precluded
the inclusion of RV-IgG data from the UK and Malawi. Briefly, 96-well plates
(Costar) coated with rabbit hyperimmune serum to rotavirus (at a dilution of 1 in
1500 for RV-IgA and 1 in 1000 for RV-IgG) were incubated with purified cell
culture lysates (WC3, at a dilution of 1 in 5 for RV-IgA and 1 in 4 for RV-IgG) or
mock-infected MA104 cells (at a dilution of 1 in 5 for RV-IgA and 1 in 4 for RV-
IgG). Serial dilutions of standard and test sera were added followed by biotinylated
rabbit anti-human IgA (Jackson ImmunoResearch Laboratories, at a dilution of 1
in 3000) for detection of RV-IgA and biotinylated rabbit anti-human IgG (Vector
Laboratories, at a dilution of 1 in 800). Absorbance was subsequently read at
492 nm. Background-corrected optical density values from sample wells were
compared with the standard curve and IgA or IgG concentration was determined
based on derived units of IgA or IgG arbitrarily assigned to the respective standard
curve, with a minimum detection limit of 1 IU/ml. Seroconversion was defined as
detection of RV-IgA at ≥20 IU/ml in previously seronegative infants or a 4-fold
increase in RV-IgA concentration among infants who were seropositive at baseline.
Rotavirus shedding. Quantification of rotavirus shedding was performed at each
study site. RNA was extracted using the RNeasy mini kit (Qiagen) following the
manufacturer’s instructions. Briefly, 10% PBS stool suspensions were defrosted on
ice, vortexed, and briefly centrifuged (10,000 × g for 10 s) to pellet larger debris.
250 μl of β-ME in buffer RTL was added to 250 μl of supernatant. The mixture was
then vortexed before the addition of 250 μl of 70% molecular-grade ethanol. The
RNeasy Mini Handbook (5th Edition, October 2013) was followed for subsequent
steps, and RNA was eluted in 50 μl RNase-free water. cDNA was generated
immediately after RNA extraction. The master mix for cDNA conversion com-
prised: 7 μl of 10× Taq DNA PCR buffer (Invitrogen), 7 μl of 50 mM MgCl2
(BIOLINE), 1 μl of Random Primers (Invitrogen), 2 μl of 10 mM dNTP (Invitro-
gen), 1 μl of DTT (Invitrogen), 2 μl of SuperScript III reverse transcriptase (Invi-
trogen), and 10 μl of RNase-free water (Invitrogen). 40 μl of eluted RNA was
denatured at 95 °C for 5 min and subsequently cooled on ice for 2 min. 30 μl of
master mix was added to each RNA sample, mixed gently by pipetting, and cen-
trifuged briefly. The tube was placed in a thermal cycler and incubated at 25 °C for
10 min, 37 °C for 1 h, then 95 °C for 5 min. The cDNA was stored at −20 °C.
Previously validated primers and probes were used for the qPCR-based
detection of rotavirus NSP239 and VP640 in two separate reactions, applying
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maximum Ct thresholds of 40 and 35, respectively. cDNA and reagents were
thawed on ice. The master mix for qPCR comprised: 12.5 μl of Platinum qPCR
supermix-UDG 2x (Invitrogen), 2 μl of 10 μM forward primer (5′-GAACTTCCT
TGAA-TATAAGATCACACTGA-3′ [NSP2] or 5′-GACGGVGCRACTACATGG
T-3′ [VP6]), 2 μl of 10 μM reverse primer (5′-TTGAAGACGTAAATGCATACC
AATTC-3′ [NSP2] or 5′-GTCCAATTCAT-NCCTGGTG-3′ [VP6]), 0.25 μl of
10 μM probe (FAM5′-TCCAATAGATTGAAGTCAGTAACGT-TTCCA-3′MGB
[NSP2] or FAM5′-CCACCRAAYATGACRCCAGCNGTA-3′MGB [VP6]), and
6.25 μl of nuclease-free water (ThermoFisher Scientific). In a 96-well plate, 23 μl of
master mix was combined with 2 μl of cDNA. Six standards for the target gene as
well as a no-template control and a positive control were added to each PCR plate.
The plate was sealed with a Microseal ‘C’ Film (Bio-Rad) and subjected to the
following cycles: initial UDG-incubation 50 °C for 2 min; denaturation for 95 °C for
2 min; then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Data were considered
valid if amplification was absent in the negative control and present in the positive
control. qPCR standards consisting of TOPO-TA plasmid constructs containing
either NPS2 or VP6 gene amplicons (genotype 1) were produced at the University
of Liverpool and distributed to the other study sites.
Inflammatory biomarkers. For infant stools collected before each dose of ORV,
MPO and α1AT concentrations were measured by ELISA at each site. ELISA kits
with the same lot number were distributed across the study sites. Stool samples
were defrosted on ice and 100 mg then aliquoted into a polypropylene tube. ELISAs
were carried out following the manufacturer’s instructions (IDK 2018 instructions
for MPO and BioVendor RIC6200 for α1AT). Paired samples from a given infant
were run on the same plate, and MPO and α1AT assays were carried out in tandem
to avoid freeze—thaw cycles. For week 6 serum samples of Indian and Malawian
infants, α1AG was measured at CMC, Vellore, using a commercial ELISA kit
(abcam) according to the manufacturer’s instructions. α1AG assays were not
performed for the UK so that the limited sample volumes for this population could
be prioritised for RV-IgA assays.
DNA extraction from stool. DNA extraction from stool was carried out using the
QIAamp DNA stool mini kit (Qiagen) according to the manufacturer’s instructions
(QIAamp DNA Stool Handbook 06/2012), with several modifications to increase
DNA yield. Briefly, the vortexed suspension of ASL buffer and stool was added to
370 mg of 0.1 mm zirconia-silicate beads (BioSpec) with 1.67 μl of lyzozyme
at 30 mg/ml (Sigma-Aldrich). Samples were then incubated at 37 °C on a shaker
(Eppendorf Thermo Mixer Comfort) at 250–300 rpm for 10 min. 10 μl of protei-
nase K (Qiagen), 50 μl of 10% sodium dodecyl sulphate (Sigma-Aldrich), and 20 μl
of RNase A (1 mg/ml; Sigma-Aldrich) were added before incubation on a heating
block (Eppendorf Thermo Mixer Comfort) at 70 °C for 10 min. After allowing the
samples to cool for 3 min, bead beating was performed for 5 min using a Tissue
Lyser II (Qiagen) at 25 Hz. Samples were microcentrifuged at 16,100 × g for 1 min
and the supernatant was then transferred into a new microcentrifuge tube con-
taining an InhibitEX tablet and vortexed for 1 min. The suspension was incubated
at room temperature for 1 min, centrifuged at 16,100 × g for 5 min, and the
supernatant (~600 μl) then transferred into a new 2ml tube. The supernatant was
centrifuged at 16,100 × g for 3 min, then 400 μl added to a 2 ml tube containing
400 μl of buffer AL. 400 μl of ethanol (96–100%) was added to the lysate and mixed
by vortexing. The manufacturer’s instructions were then resumed until elution in
50 μl of AE Buffer. An extraction control was carried out with each batch of DNA
extraction at all sites. Extracted DNA was shipped from India and Malawi to the
University of Liverpool on dry ice for 16S rRNA sequencing.
Amplicon generation for 16S rRNA sequencing. Amplicons spanning 16S rRNA
gene variable regions 3 and 4 (primers 309F 5′-ACTCCTACGGGAGGCAGCAG-3′
and 819 R 5′-GGACTACHVGGGTWTCTAAT-3′) were produced following the
established Illumina protocol (Illumina, 16S Metagenomic Sequencing Library
Preparation Protocol Part # 15044223 Rev. B) with the following amendments: 1 μl
of DNA was used as a starting template; NEBNext Q5 Hot Start HiFi PCR Master
Mix (NEB) was used for amplicon and indexing PCRs; PCR reaction volumes were
halved to 25 μl; primers were used at a concentration of 10 μM; and 20 μg of
molecular-grade bovine serum albumin (NEB) was added to the amplicon PCR
master mix to mitigate the effect of PCR inhibitors. Cycling conditions for amplicon
PCR involved: denaturation at 98 °C for 30 s; 10 cycles of 98 °C for 10 s, 55 °C for
15 s, and 72 °C for 40 s; and final extension at 72 °C for 60 s. Cycling conditions for
indexing PCR involved: denaturation at 98 °C for 3 min; 15 cycles of 98 °C for 10 s,
55 °C for 15 s, and 72 °C for 40 s; and final extension at 72 °C for 5 min. AMPure XP
beads were substituted with a custom preparation of Sera-Mag SpeedBeads Protein
A/G particles (MERCK/GE Healthcare) throughout the protocol. To determine
volumes required for equimolar pooling, amplicon concentrations were determined
by Quanti-it (ThermoFisher Scientific) and size distributions by fragment analysis
on a 5300 Fragment Analyzer System (Agilent). Amplicons were pooled using a
mosquito X1 (TTP Labtech) liquid handling robot. The final library underwent size
selection to remove potentially contaminating primer-dimers and genomic DNA
using the Pippin Prep (Sage Science) 1.5% Agarose Gel Cassette (Labtech).
Overall, we sequenced amplicons from 2138 samples across 14 Illumina
HiSeq2500 lanes (v2 chemistry, 600 cycles in rapid run mode) and one Illumina
MiSeq lane (v3 chemistry, 600 cycles). Since enrolment and sample collection
across the three sites were not synchronised, sequencing was batched by geographic
origin according to sample availability. Samples from a mother–infant pair were
processed on the same PCR plate. Each PCR plate contained a no-template PCR
control, stool controls provided by a mother and infant in the UK who were not
enrolled in the study, DNA from a mock community (Zymo Research D6306), and
a pool of extraction controls corresponding to the samples contained on the PCR
plate. Final libraries consisted of up to four PCR plates (384 amplicons). Eight
samples were excluded from the analysis owing to the presence of significant
amplification from their corresponding extraction controls.
Illumina sequencing of 16S rRNA libraries. The quantity and quality of each
amplicon pool was assessed by Qubit dsDNA High Sensitivity Assay Kit (Ther-
moFisher Scientific), Bioanalyzer High Sensitivity DNA Kit (Agilent), and qPCR
using the KAPA Library Quantification Kit (Roche) on a Light Cycler LC480II
(Roche) according to the manufacturer’s instructions. qPCR data were used to
calculate sample molarity. 5 μl of the final pool was denatured for 5 min at room
temperature using 5 μl of freshly diluted 0.1 N sodium hydroxide (Illumina). The
reaction was subsequently terminated by the addition of HT1 hybridization buffer
(Illumina) and the library diluted post-denaturation to a final loading concentra-
tion of 7–8.5 pM. Libraries were sequenced with 10–20% PhiX (Illumina) using the
2 × 300 bp paired-end protocol.
Independent validation of 16S rRNA sequencing. To validate the robustness of
the microbiota protocol, 10% of DNA samples were shipped to Imperial College
London and sequenced according to the methods described above. We included 30
mother–infant pairs per study site in the validation subset and sequenced two
infant stools (from weeks 1 and 10/12) and the maternal stool from each pair.
Protocol deviations included the use of AMPure XP beads for PCR product pur-
ification, fragment analysis via TapeStation D1000 ScreenTape (Agilent), amplicon
quantification for individual samples via Qubit dsDNA High Sensitivity Assay Kit
(ThermoFisher Scientific), and manual pooling of equimolar quantities. The order
of samples was randomised across three PCR plates and the pooled libraries were
sequenced with 10–20% PhiX (Illumina) on two 2 × 300 bp paired-end Illumina
MiSeq runs (v3 chemistry).
Bioinformatic processing of sequence data. Adapters were trimmed from raw
sequences using cutadapt version 1.1841. Subsequent steps for quality filtering,
denoising, merging of paired reads, and chimera removal followed the DADA2
pipeline42 implemented in QIIME 2 (version 2018.11) with default parameters43.
Forward reads were truncated to 270 bp and reverse reads to 200 bp to account for
the fall in sequencing quality scores towards the end of each read. Sequence data
were processed separately for each run, and the feature tables and corresponding
sequences then merged. All subsequent steps were performed in the programming
language R (version 3.6.1). Taxonomy assignment was performed via the R package
dada2 (version 1.14.1) using the RDP naive Bayesian classifier trained on the Silva
rRNA database (version 132). Sequence variants were included in the analysis if
they were 390–440 bp in length, bacterial, detectable at an abundance of ≥0.1% in
at least two samples, and passed frequency-based contamination filtering using the
decontam package (version 1.6), which screens sequences that are more abundant
in low-concentration samples44. Nanodrop concentrations (ng/μl) of extracted
DNA served as the basis for contaminant filtering. Samples with at least 25,000
quality-filtered sequences were retained in the final analysis. For visualisation
purposes, neighbour-joining trees were constructed at genus level based on JC69
distances, using the sequence of the most abundant RSV as the reference for
each genus.
Statistical analysis. All analyses were performed in the programming language R.
Participants with complete data were included in each analysis. Seroconversion and
shedding proportions were compared by country using pairwise two-sided Fisher’s
exact tests with Benjamini–Hochberg FDR correction. Antibody and inflammatory
biomarker concentrations were log transformed and compared by country and
shedding subgroup (see Supplementary Fig. 1B) using ANOVA with post-hoc
Tukey tests. Maternal breastmilk/serum RV-IgA ratios were calculated using log-
transformed antibody concentrations and compared by country using Dunn’s test
(given their highly skewed distribution). We explored covariates associated with
seroconversion, ORV shedding, and neonatal infection status via logistic regres-
sion, and those associated with log-transformed post-vaccination RV-IgA via linear
regression and Pearson’s r with two-sided hypothesis testing. Following these
univariate analyses, variables with p values of <0.05 were explored in multivariate
models for each ORV outcome. Where multiple correlated variables were eligible
for inclusion in multivariate models, we minimised multicollinearity by prioritising
variables measured closer to the first dose of ORV (e.g. Shannon index at 6 weeks
of life vs 4 weeks of life), maternal antibodies in serum versus breastmilk, and
maternal serum RV-IgG versus maternal RV-IgA or pre-vaccination infant RV-
IgG. In Indian mother–infant dyads, a correlation network was also calculated
between all measured antibody concentrations (RV-IgG and RV-IgA) and rotavirus
shedding quantities (reciprocal of qPCR Ct value) using Spearman’s rank
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correlation coefficients with two-sided hypothesis testing. Clopper–Pearson 95%
confidence intervals were used for the reporting of proportions.
Ward’s minimum variance hierarchical clustering method was used to visualise
all infant and maternal gut microbiota samples based on the presence or absence of
common genera (≥1% prevalence across all samples). For cross-sectional analyses
of alpha diversity, we used ANOVA with post-hoc Tukey tests (country) or linear
regression (ORV outcome and neonatal rotavirus infection status). For cross-
sectional analyses of beta diversity, we determined the proportion of variation in
genus-level unweighted Bray–Curtis distances associated with country and ORV
outcome via PERMANOVA with 999 permutation. A minimum abundance
threshold of 0.1% was used when calculating Bray–Curtis distances. To identify
discriminant taxa according to country or binary ORV outcomes (seroconversion
and shedding), we used two-sided Fisher’s exact test (differences in prevalence) and
Aldex2 (two-sided Wilcoxon rank-sum test of centred log-ratio transformed
sequence counts), classifying taxa as discriminant if they had an FDR-adjusted p
value of <0.05 based on either method. Aldex2 was also used to identify taxa
correlated with log-transformed post-vaccination RV-IgA (FDR-adjusted p value of
<0.05 based on two-sided Spearman’s rank test). Taxa were included if they were
detected with a prevalence of >5% in at least one of the groups being compared.
We performed an exploratory analysis to identify demographic covariates
associated with alpha diversity (via linear regression) or beta diversity (via
PERMANOVA of genus-level unweighted Bray–Curtis distances) at the time of the
first ORV dose. To account for multiple testing in this exploratory analysis, we
report on variables with FDR-adjusted p value of <0.05.
To complement the cross-sectional analyses at each sampling timepoint, we
took advantage of the longitudinal study design to explore variation in microbiota
diversity and genus abundance across early infancy. Longitudinal mixed-effects
models were used to compare Shannon index by country (pairwise comparisons
with FDR correction), ORV outcome (seroconversion and dose 1 shedding status),
and neonatal rotavirus infection, including week of life as a covariate (to account
for age-associated changes in microbiota composition) and study ID as a random
effect. For common genera (>20% across infant samples in a given country), we
used longitudinal zero-inflated negative binomial models of sequence counts to
identify taxa that discriminated infants according to country or ORV outcome,
adjusting for age (by including week as a fixed effect) and including study ID as a
random effect. A threshold of 20% was selected based on prior validation of this
statistical modelling approach in the context of microbiome proportion data45. For
taxa with a prevalence of >95%, negative binomial models without zero inflation
were used.
For technical replicates (including positive controls and samples selected for
independent validation), we quantified the proportion of variance explained by
sample ID using linear regression (Shannon index, genus abundances) or
PERMANOVA with 999 permutations (unweighted Bray–Curtis distances). We
also used PERMANOVA to quantify the proportion of variation in microbiota
composition associated with sequencing run, stratified by age and country.
Random Forests. We applied the Random Forests algorithm in a series of cross-
sectional analyses to predict country, seroconversion, or shedding status (classifi-
cation approach), or post-vaccination log-transformed RV-IgA concentration
(regression approach) based on genus or RSV relative abundances. Taxa were
included if they were detected with a prevalence of >5% in at least one of the
groups being compared. For each analysis, we performed 20 iterations of 5-fold
cross-validation. For classification models, we standardised the baseline accuracy at
50% by fitting each iteration of 5-fold cross-validation on a random subset of
50 samples per group (or the number of samples in the minority group if this was
<50). Models were excluded if there were <10 samples in the minority group. For
regression models, out-of-bag R2 values for predicted vs observed RV-IgA values
were determined via linear regression. Mean cross-validation variable importance
was determined based on the increase in Gini index (classification) or mean
squared error (regression) of out-of-bag sample prediction following random
permutation. For Indian infants, we assessed additional models based on a com-
bination of demography/baseline health measurements (18 variables), exposure/
antibody data (12 variables, encompassing inflammatory biomarkers, neonatal
rotavirus infection status, and maternal antibodies), and genus relative abundances
at the time of the first ORV dose (55 variables, encompassing genera present in
>5% of samples).
Sample size. As reported in the published protocol37, we calculated that a sample
size of 150 infants in India and Malawi would provide 80% power to detect a two-
fold higher mean concentration of RV-IgG in infants who fail to seroconvert
compared with those who seroconvert (assuming 40% seroconversion in each),
while a sample size of 50 in the UK would provide 79% power to detect significant
differences in RV-IgA by seroconversion status across the study sites (assuming
95% seroconversion in the UK). These sample sizes would also provide 95% power
to detect significant differences in Shannon index according to seroconversion
status in India and Malawi. The sample size in India (n= 307) exceeded these
targets owing to the high recruitment rates in this cohort and the decision to merge
the IPV and OPV arms in the final analysis. On the other hand, owing to chal-
lenges in recruitment and sample collection over the course of the study, the final
samples size in Malawi (n= 119) fell short in these estimates. Since RV-IgG data
were not available for the UK and Malawi, our final analyses of maternal antibodies
across cohorts focused on RV-IgA.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw sequence data generated during this study have been deposited in the European
Nucleotide Archive under accession code PRJEB38948. Processed data are available on
Github (https://github.com/eparker12/RoVI; https://doi.org/10.5281/zenodo.5528337)46.
Taxonomy assignment was performed using the Silva rRNA database (version 132;
https://doi.org/10.5281/zenodo.1172782).
Code availability
Analysis code generated during this study are available on Github (https://github.com/
eparker12/RoVI; https://doi.org/10.5281/zenodo.5528337).
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